Healthcare AI startup Promedius (CEO Hyunjin Bae) announced that it participated as a Platinum Sponsor at the Asia Pacific Consortium on Osteoporosis (APCO) Conference in Singapore from July 17-19.

The APCO Congress is a significant academic summit that brings together the world's leading osteoporosis experts, including Prof. Jean-Yves Reginster, Chairman of ESCEO, and Dr. Philippe Halbout, CEO of the International Osteoporosis Foundation (IOF), to discuss and share their views on osteoporosis treatment and the latest clinical research trends. As the main sponsor of the luncheon symposium, Promedius presented PROS® CXR: OSTEO, a CXR-based osteoporosis screening AI solution, which has been appreciated as a breakthrough solution for early detection of osteoporosis and fracture prevention.

The presentation was led by Dr. Miso Jang, MD, PhD, the medical director of Promedius, and Dr. Hisham Badaruddin, MD, PhD, a professor at Duke-NUS Medical School and a local Key Opinion Leader (KOL) of Promedius, who presented the latest research results and projected benefits of PROS® CXR: OSTEO.

"PROS® CXR: OSTEO will contribute in establishing an environment for proactive osteoporosis screening, enabling asymptomatic patients to receive timely diagnosis and treatment," said Dr. Miso Jang. "By making diagnosis more accessible through utilization of the most commonly ordered X-ray, we can dramatically reduce the risk of fracture."

"PROS® CXR: OSTEO is remarkable for its ability to rapidly screen a large number of patients in primary care," said Dr. Hisham. “In its real-world clinical applications, the easy installation and intuitive analysis results will improve clinician efficiency and serve as an essential tool for osteoporosis diagnosis, especially in the Asia-Pacific region with a rapidly-aging population."

Through its participation in the APCO Congress, ProMedius plans to demonstrate its technology in the global market and seek collaboration with more healthcare organizations. "We are very pleased to be participating as a Platinum Sponsor at the APCO Congress," said Sunghyun Jung from Promedius. "We look forward to interacting with many experts at the conference and spreading the word about the exceptional performance of PROS® CXR: OSTEO."

Promedius will continue to advance its technology for the early diagnosis and prevention of osteoporosis and other musculoskeletal disorders. This will help improve the quality of life of older adults worldwide and reduce the societal costs of osteoporosis.